CalciMedica (CALC) Non-Current Deffered Revenue (2020 - 2021)
CalciMedica's (CALC) quarterly Non-Current Deffered Revenue came in at $8000.0 in Q4 2021, down 27.27% YoY from $11000.0 in Q4 2020, and down 33.33% on a QoQ basis from $12000.0 in Q3 2021.
CalciMedica (CALC) Non-Current Deffered Revenue (2020 - 2021) Analysis & Trends
CalciMedica (CALC) has 2 years of Non-Current Deffered Revenue data on file, last reported at $8000.0 in Q4 2021.
- Quarterly Non-Current Deffered Revenue fell 27.27% year-over-year to $8000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $8000.0 (down 27.27% YoY) and the FY2021 annual result came in at $8000.0, down 27.27% from the prior year.
- Non-Current Deffered Revenue eased to $8000.0 in Q4 2021, from $12000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $13000.0 in Q2 2021 to a low of $8000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | CalciMedica | 9.80 Mn | -8.82 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 8,000.00 |
| Sep 30, 2021 | 12,000.00 |
| Jun 30, 2021 | 13,000.00 |
| Mar 31, 2021 | 12,000.00 |
| Dec 31, 2020 | 11,000.00 |
| Sep 30, 2020 | 10,000.00 |